Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 29;8(2):193-207.
doi: 10.1002/mdc3.13129. eCollection 2021 Feb.

Movement Disorders and Hematologic Diseases

Roshni Abee Patel  1 , Deborah A Hall  1 , Sheila Eichenseer  2 , Meagan Bailey  1
Affiliations
Review

Movement Disorders and Hematologic Diseases

Roshni Abee Patel et al. Mov Disord Clin Pract. .

Abstract

Background: Movement disorders can be associated with or caused by hematological abnormalities. The objective of this review is to highlight features that will aid in the clinician's recognition and treatment of these disorders.

Methods: MESH terms relevant to movement disorders and hematologic diseases were searched to identify conditions included in this narrative, educational review.

Results: Several conditions were identified, and they were organized by hematologic categories to include red blood cell abnormalities, white blood cell abnormalities, disorders of clotting and bleeding, hematologic malignancies, and others.

Conclusions: This review will increase providers' understanding of disorders that include movement disorders and hematologic abnormalities. Basic hematologic laboratories can aid in assessment of these disorders, to include complete blood count/hemogram and peripheral blood smear. Recognition is key, especially in the setting of underlying malignancy, vitamin deficiency, or other disorder in which treatment is available.

Keywords: movement disorders, hematology, anemia, acanthocytes, thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

There were no sources of funding for this work and the authors have no conflicts of interest to declare.

References

    1. Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis 2008;3(1):19 10.1186/1750-1172-3-19. - DOI - PMC - PubMed
    1. Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis 2014;37(3):333–339. 10.1007/s10545-013-9665-4. - DOI - PubMed
    1. Walker RH, Jankovic J, O'Hearn E, Margolis RL. Phenotypic features of Huntington's disease‐like 2. Mov Disord 2003;18(12):1527–1530. 10.1002/mds.10587. - DOI - PubMed
    1. Anderson DG, Ferreira‐Correia A, Rodrigues FB, et al. Comparison of the Huntington's disease like 2 and Huntington's disease clinical phenotypes. Mov Disord Clin Pract. 2019;6(4):302–311. 10.1002/mdc3.12742. - DOI - PMC - PubMed
    1. Seixas AI, Holmes SE, Takeshima H, et al. Loss of junctophilin‐3 contributes to Huntington disease‐like 2 pathogenesis. Ann Neurol 2012;71(2):245–257. 10.1002/ana.22598. - DOI - PubMed

LinkOut - more resources